BioSpace News Archive

Cara Therapeutics, Inc. today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA ® IV Injection Syringe for the treatment of pruritus in hemodialysis patients.

Theratechnologies Inc. today announced that it has reached an agreement in principle to amend some of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time (the “Loan Facility”), with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).

AbbVie announced that the European Commission has granted conditional marketing authorization for TEPKINLY® as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Jasper Therapeutics, Inc. today announced the appointment of Herb Cross, an experienced senior financial executive, as the company’s Chief Financial Officer (CFO).

GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced the company will present at the LD Micro Main Event XVI 2023 in Los Angeles, CA, on Wednesday, October 4, 2023, at 12:30 p.m. Pacific Time.

Viridian Therapeutics, Inc. today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human glioblastoma multiforme (GBM) tumors.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 26th at 1:00 pm ET.

Pain Relief Technology, LLC, a newcomer to the wellness industry, has unveiled the Bax-si, its flagship, eponymous device, designed to provide non-invasive pain relief for those who suffer from lower back discomfort.

Tris Pharma, Inc. today announced that Health Canada has authorized the use of Quillivant ® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12.